Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3795 Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors – A pooled analysis of five clinical trials

Introduction: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in systemic oncological therapies is still unknown, and there is a lack of evidence, especially in uncommon neoplasms like neuroendocrine tumors (NET).

Conference:

Presenting Author:

Authors: Hernando Cubero J, Roca-Herrera M, Garcia Alvarez A, Raymond E, Kulke M,

Keywords: Sex, Toxicity, Tyrosine Kinase Inhibitor,

#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate

Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Raymond E, Kulke M, Qin S, Yu X, Schenker M,

Keywords: pNET, survival, sunitinib,

#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover

Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raymond E

Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,

Keywords: sutent, OS,

#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)

Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Raymond E, Harmon C, Niccoli P, Metrakos P, Borbath I,

Keywords: Sunitinib, phase 3, pancreatic neuroendocrine tumor, Ki-67 index, prior treatment, prognostic factor,

#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors

Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Raymond E

Authors: Raymond E, Seitz J, Bang Y, Borbath I, Lombard-Bohas C,

Keywords: Sunitinib, phase III, pancreatic neuroendocrine tumor ,